Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
Vizient, Inc.

2. Address

Address1
799 9th St NW
 Address2
​Suite 210
City
WASHINGTON
 State
DC
 Zip Code
20001
 Country
USA

3. Principal place of business (if different than line 2)

City
​Irving
 State
​TX
 Zip Code
​75062
 Country
​USA
4a. Contact Name b. Telephone Number c. E-mail
​Mrs.
​Shoshana Krilow
​2023542607
​shoshana.krilow@vizientinc.com
5. Senate ID#
​40021-00012
7. Client Name Self Check if client is a state or local government or instrumentality
​Vizient, Inc.
6. House ID#
​313240000
TYPE OF REPORT 8. Year
​2026
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​
$5,000 or more $
​320,000.00
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: Shoshana Krilow
 Date
4/20/2026 7:55:49 PM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Advanced Notice of Proposed Rulemaking: Medicare Program; Ensuring Safety through Domestic Security with Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals (CMS-1516-ANPRM) - Responded to various issues and proposals provided in the ANPRM, encouraged non-budget neutral Medicare payments to incentivize domestic procurement

Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (Docket No.: CMS-2025-1393) - Responded to various issues in the proposed rule regarding the Medicare Advantage/Part C and the Medicare Prescription Drug Benefit (Part D) program and Quality Rating System (Star Ratings).

Global Benchmark for Efficient Drug Pricing (GLOBE) Model Proposed Rule (CMS5545-P) - Responded to various issues and proposals provided in the Proposed Rule, emphasized aligning reimbursement model with performance

Monitored development and passage of the Consolidated Appropriations Act, 2026 (H.R. 7148)

Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program Proposed Rule (CMS-9883-P) - Responded to various issues and proposals provided in the Proposed Rule

Provider payment - Supported changes to Medicare/Medicaid provider payment system and increased hospital reimbursements. Advocated for reimbursement rates that reflect the true cost of care, particularly for hospitals serving vulnerable and rural populations.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Shoshana
Krilow
​
​
Jenna
Stern
​
​
Darren
Webb
​
​
Alexandria
Icenhower
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Continued healthcare access - Advocated for a more resilient healthcare infrastructure and policies that provide the staffing and technological infrastructure necessary to maintain essential services

Continued monitoring and encouraged passage of the Biosimilar Red Tape Elimination Act (S.1954)

Continued monitoring and encouraged passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (S.1784/H.R.4191)

Continued monitoring and encouraged passage of the Protect Medicaid and Rural Hospitals Act (S.2279)

Continued monitoring and encouraged passage of the Protecting Health Care and Lowering Costs Act (S.2556)

Continued monitoring and encouraged passage of the Resident Physician Shortage Reduction Act of 2025 (S.2439/H.R.3890/H.R.4731)

Continued monitoring and encouraged passage of the Save Healthcare Workers Act (S.1600/H.R.3178).

Draft Guidance for Industry, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies (Docket No. FDA-2011-D-0605) - Urging FDA to streamline biosimilar approval for increased patient access to cost-effective treatment alternatives

Drug shortages - Supported elements to increase transparency in prescription drug supply chain and increase reimbursement for generic prescription drugs; issues related to compounding; issues related to buffer inventory. Encouraged improved stakeholder communication and increased notification by manufacturers for surges in demand

Hospital Group Purchasing - Advocated to highlight the value that hospital group purchasing organizations (GPOs) provide to hospitals and suppliers. Provided education on how GPOs work in the healthcare supply chain and the role they play in delivering value to healthcare providers, as well as key differences between traditional GPOs and PBMs.

Monitored development and introduction of the Drug Origin Transparency Act of 2025 (HR.8339)

Monitored development and passage of the Consolidated Appropriations Act, 2026 (H.R. 7148)

Payer-mandated White Bagging - Urged support for policy updates related to payer-mandated white bagging for medications

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Shoshana
Krilow
​
​
Jenna
Stern
​
​
Darren
Webb
​
​
Alexandria
Icenhower
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

Continued monitoring and encouraged passage of the Medical Supply Chain Resiliency Act (S.998/HR.2213)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Shoshana
Krilow
​
​
Alexandria
Icenhower
​
​
Darren
Webb
​
​
Jenna
Stern
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAR

16. Specific lobbying issues

Continued monitoring and encouraged passage of the Medical Supply Chain Resiliency Act (S.998/HR.2213)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Shoshana
Krilow
​
​
Alexandria
Icenhower
​
​
Darren
Webb
​
​
Jenna
Stern
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​
​
​
3
​
​
​
2
​
​
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​TAX
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)